Clinical Research Division, Fred Hutch
Dr. Shailender Bhatia aims to improve outcomes for people with kidney cancers and skin cancers, especially melanoma and Merkel cell carcinoma. He leads clinical trials of new immunotherapies and targeted, less-toxic therapies for patients with these diseases.
Dr. Bhatia’s research efforts are mostly focused on clinical trials that aim at improving outcomes in skin cancers (especially Melanoma and Merkel cell carcinoma). He is especially interested in those novel therapeutic approaches that stimulate the immune system against cancer and those that target therapy to the tumors in order to spare unnecessary toxicity.
Study Number: 9820
Study Number: 1256914
Study Number: 20152209
Study Number: RG1003448
Study Number: RG1718055
Study Number: UW15057
The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.
Email email@example.com or call 206.667.2210.